Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Feb;23(2):219–227. doi: 10.1111/j.1365-2125.1987.tb03033.x

Acute and subchronic effects of Org 2305 and diazepam on psychomotor performance in man.

M J Mattila, J Koski, C Strömberg
PMCID: PMC1386072  PMID: 2881574

Abstract

Three doses (15, 30 and 60 mg) of Org 2305 (O 15, O 30 and O 60 respectively), a novel anxiolytic drug chemically related to mianserin, were compared with placebo and 15 mg diazepam (DZ) on human psychomotor performance in a double-blind, cross-over study with 15 healthy volunteers. Objective measurements (choice reaction, tracking, flicker fusion, Maddox wing, digit symbol substitution, memory recall) and subjective assessments (visual analogue scales) were done at baseline and 2 and 13 h after the first dose. This testing procedure was repeated on day 7 when administering the seventh consecutive daily night-time dose. After the first dose O 15 did not differ from placebo and O 30 rarely differed from placebo. O 60 impaired various objective functions similarly to, or less than DZ. Subjectively, DZ and O 60 were felt as sedative. During subchronic treatment, DZ caused some impairment of baseline due to accumulation of bioassayable benzodiazepines, but significant responses to the last DZ dose were less than those to the first dose. DZ but not O 60 was reported to have caused lethargy and clumsiness during subchronic treatment. In the doses used Org 2305 impaired psychomotor performance less than diazepam did. A dose of 60 mg Org 2305 may offer some advantage over 15 mg diazepam, provided that their anxiolytic effects are about similar.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aranko K., Mattila M. J., Bordignon D. Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow-up phase. Acta Pharmacol Toxicol (Copenh) 1985 May;56(5):364–372. doi: 10.1111/j.1600-0773.1985.tb01305.x. [DOI] [PubMed] [Google Scholar]
  2. Aranko K., Mattila M. J., Seppälä T., Aranko S. The contribution of the active metabolites to the tolerance developing to diazepam in man: relationship to bioassayed serum benzodiazepine levels. Med Biol. 1984;62(5):277–284. [PubMed] [Google Scholar]
  3. Aranko K., Mattila M. J., Seppälä T. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol. 1983 May;15(5):545–552. doi: 10.1111/j.1365-2125.1983.tb02088.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarke C. H., Nicholson A. N. Performance studies with antihistamines. Br J Clin Pharmacol. 1978 Jul;6(1):31–35. doi: 10.1111/j.1365-2125.1978.tb01678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. File S. E., Lister R. G. Dose tolerance to lorazepam develop with once weekly dosing? Br J Clin Pharmacol. 1983 Dec;16(6):645–650. doi: 10.1111/j.1365-2125.1983.tb02235.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fink M., Irwin P., Gastpar M., DeRidder J. J. EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). Psychopharmacology (Berl) 1977 Nov 15;54(3):249–254. doi: 10.1007/BF00426572. [DOI] [PubMed] [Google Scholar]
  7. Grünberger J., Saletu B. Determination of pharmacodynamics of psychotropic drugs by psychometric analysis. Prog Neuropsychopharmacol. 1980;4(4-5):417–434. doi: 10.1016/0364-7722(80)90012-0. [DOI] [PubMed] [Google Scholar]
  8. Hjorth S., Carlsson A. Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. Eur J Pharmacol. 1982 Sep 24;83(3-4):299–303. doi: 10.1016/0014-2999(82)90265-5. [DOI] [PubMed] [Google Scholar]
  9. Hollister L. E. Current antidepressants. Annu Rev Pharmacol Toxicol. 1986;26:23–37. doi: 10.1146/annurev.pa.26.040186.000323. [DOI] [PubMed] [Google Scholar]
  10. Irwin P., Fink M. Familiarization session and placebo control in EEG studies of drug effects. Neuropsychobiology. 1983;10(2-3):173–177. doi: 10.1159/000118005. [DOI] [PubMed] [Google Scholar]
  11. Liljequist R., Mattila M. J. Acute effects of temazepam and nitrazepam on psychomotor skills and memory. Acta Pharmacol Toxicol (Copenh) 1979 May;44(5):364–369. doi: 10.1111/j.1600-0773.1979.tb02346.x. [DOI] [PubMed] [Google Scholar]
  12. Mattila M. J., Liljequist R., Seppälä T. Effects of amitriptyline and mianserin on psychomotor skills and memory in man. Br J Clin Pharmacol. 1978;5 (Suppl 1):53S–55S. [PMC free article] [PubMed] [Google Scholar]
  13. McMillen B. A., McDonald C. C. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. Neuropharmacology. 1983 Mar;22(3):273–278. doi: 10.1016/0028-3908(83)90240-x. [DOI] [PubMed] [Google Scholar]
  14. Nicholson A. N., Stone B. M. Antihistamines: impaired performance and the tendency to sleep. Eur J Clin Pharmacol. 1986;30(1):27–32. doi: 10.1007/BF00614191. [DOI] [PubMed] [Google Scholar]
  15. Pinder R. M., Van Delft A. M. The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol. 1983;15 (Suppl 2):269S–276S. doi: 10.1111/j.1365-2125.1983.tb05875.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Seppälä T., Aranko K., Mattila M. J., Shrotriya R. C. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther. 1982 Aug;32(2):201–207. doi: 10.1038/clpt.1982.148. [DOI] [PubMed] [Google Scholar]
  17. Seppälä T. Psychomotor skills during acute and two-week treatment with mianserin (ORG GB 94) and amitriptyline, and their combined effects with alcohol. Ann Clin Res. 1977 Apr;9(2):66–72. [PubMed] [Google Scholar]
  18. Stone B. M. Pencil and paper tests--sensitivity to psychotropic drugs. Br J Clin Pharmacol. 1984;18 (Suppl 1):15S–20S. doi: 10.1111/j.1365-2125.1984.tb02578.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES